💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tezacaftor

CHEMBL3544914 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
520.5 g/mol
LogP
2.9
Phase
4

Tezacaftor is a CFTR corrector that binds to the misfolded CFTR protein (particularly the F508del mutant) and facilitates its proper folding and trafficking to the cell surface, where it can function as a chloride channel in cystic fibrosis patients. It is used in combination with ivacaftor (a CFTR potentiator) to treat cystic fibrosis in patients with F508del and other responsive mutations. This combinatorial approach of correcting protein folding and enhancing channel gating addresses two distinct molecular defects in CFTR dysfunction.

Khối lượng phân tử

520,5000 g/mol

LogP

2,90

TPSA

113,00 Ų

Lipinski RO5

Đạt

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO

                

                

                
                

                    
InChI

                    
InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C26H27F3N2O6

                    

                    
                    

                        
HBD / HBA

                        
4 / 9

                    

                    
                    

                        
Liên kết có thể quay

                        
8

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
37

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
Tezacaftor is a CFTR corrector that binds to the misfolded CFTR protein (particularly the F508del mutant) and facilitates its proper folding and trafficking to the cell surface, where it can function as a chloride channel in cystic fibrosis patients. It is used in combination with ivacaftor (a CFTR potentiator) to treat cystic fibrosis in patients with F508del and other responsive mutations. This combinatorial approach of correcting protein folding and enhancing channel gating addresses two distinct molecular defects in CFTR dysfunction.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Tezacaftor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3544914.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 46199646.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.